X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FRESENIUS KABI ONCO. - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FRESENIUS KABI ONCO. NOVARTIS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 393.4 22.1 1,777.6% View Chart
P/BV x 19.4 3.1 622.2% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 NOVARTIS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NOVARTIS
Mar-16
FRESENIUS KABI ONCO.
Mar-13
NOVARTIS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs982176 558.0%   
Low Rs55679 708.5%   
Sales per share (Unadj.) Rs252.937.7 671.1%  
Earnings per share (Unadj.) Rs62.15.1 1,220.1%  
Cash flow per share (Unadj.) Rs63.36.7 941.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.642.5 854.7%  
Shares outstanding (eoy) m31.96158.23 20.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.03.4 90.1%   
Avg P/E ratio x12.425.0 49.5%  
P/CF ratio (eoy) x12.218.9 64.2%  
Price / Book Value ratio x2.13.0 70.7%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,58020,135 122.1%   
No. of employees `0000.81.2 65.3%   
Total wages/salary Rs m1,801703 256.1%   
Avg. sales/employee Rs Th10,748.95,176.2 207.7%   
Avg. wages/employee Rs Th2,395.2610.4 392.4%   
Avg. net profit/employee Rs Th2,641.1699.6 377.5%   
INCOME DATA
Net Sales Rs m8,0835,963 135.6%  
Other income Rs m82918 4,607.8%   
Total revenues Rs m8,9135,981 149.0%   
Gross profit Rs m2341,430 16.4%  
Depreciation Rs m37258 14.2%   
Interest Rs m2-26 -6.9%   
Profit before tax Rs m1,0251,216 84.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696-68 -2,490.9%   
Tax Rs m752342 219.8%   
Profit after tax Rs m1,986806 246.4%  
Gross profit margin %2.924.0 12.1%  
Effective tax rate %73.428.1 260.7%   
Net profit margin %24.613.5 181.8%  
BALANCE SHEET DATA
Current assets Rs m12,6785,102 248.5%   
Current liabilities Rs m2,4332,385 102.0%   
Net working cap to sales %126.745.6 278.2%  
Current ratio x5.22.1 243.6%  
Inventory Days Days33150 21.8%  
Debtors Days Days22113 19.8%  
Net fixed assets Rs m695,148 1.3%   
Share capital Rs m160158 101.0%   
"Free" reserves Rs m11,4606,556 174.8%   
Net worth Rs m11,6216,732 172.6%   
Long term debt Rs m0952 0.0%   
Total assets Rs m14,40010,388 138.6%  
Interest coverage x570.5-45.8 -1,246.3%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 97.8%   
Return on assets %13.87.5 183.9%  
Return on equity %17.112.0 142.8%  
Return on capital %23.614.6 161.4%  
Exports to sales %0.774.5 1.0%   
Imports to sales %18.624.8 75.0%   
Exports (fob) Rs m604,441 1.4%   
Imports (cif) Rs m1,5031,477 101.7%   
Fx inflow Rs m1865,298 3.5%   
Fx outflow Rs m1,8211,772 102.7%   
Net fx Rs m-1,6353,525 -46.4%   
CASH FLOW
From Operations Rs m2,5311,274 198.6%  
From Investments Rs m-8,270-1,204 686.7%  
From Financial Activity Rs m-386-196 196.7%  
Net Cashflow Rs m-6,125-126 4,849.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 2.0 0.3 666.7%  
FIIs % 1.6 9.6 16.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 9.1 236.3%  
Shareholders   41,647 42,599 97.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  SANOFI INDIA  DR. DATSONS LABS  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 23, 2018 11:07 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STRIDES SHASUN LTD COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS